Novavax Stock News

Novavax will struggle to succeed in the fading coronavirus vaccine market. Approval for the company's other candidates still looks some ways away.

Novavax is working on drastically reducing its expenses this year. Its business still centers largely around COVID, and to a lesser extent a flu vaccine.

Novavax was an early pandemic success story, surging more than 2,000% as investors bet on its coronavirus vaccine. But when the vaccine fell behind, the stock tumbled and hasn't yet recovered.

One secret to making money in the markets is to keep holding winners and exit the losers as soon as a red flag appears. Investors need to keep aside biases and ego if the target is to make wealth from

Following last year's big rally, the stock market is off to a slow start in 2024. After two weeks the S&P 500 index is essentially flat.

Novavax, Inc. (NVAX) CEO John Jacobs Presents at JPMorgan 42nd Annual Healthcare Conference Transcript

As a critical mass of risk-hungry traders now believe “the coast is clear,” now may be the perfect time to consider which meme stocks to short. What do I mean by “the coast is clear?

There was a time when investors used to avoid heavily shorted stocks. Building-up of short interest indicates a bearish view of the stock, translating into a sustained correction.

During the meme stocks rally of 2021, it seemed that all potential meme stocks skyrocketed. The speculative activity peaked, and short-squeeze rallies delivered multi-bagger returns in weeks.

Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older.

Novavax's prospects in the COVID-19 vaccine market look uncertain. The rest of the company's pipeline doesn't look inspiring.

Short squeezes, which are characterized by sudden and substantial surges in asset prices, have become prominent and debated phenomena on Wall Street in recent years. A short squeeze occurs when a high

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company